logo
Share SHARE
FONT-SIZE Plus   Neg

Optimer's DIFICID Benefits Adult Cancer Patients With CDAD In Studies

Optimer Pharmaceuticals, Inc. (OPTR) said Friday that results from a post-hoc subgroup analysis of the company's two large Phase 3 trials showed cancer patients with Clostridium difficile-associated diarrhea had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID tablets compared to oral vancomycin.

The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases in London.

The analysis included 153 patients with active cancer who were treated in the two DIFICID Phase 3 studies and who received 8 days or more of treatment with DIFICID or oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence.

Infections caused by C. difficile and the resulting diarrhea pose a significant threat to cancer patients, mainly those with compromised immune systems due to chemotherapy or stem cell transplants.

"The results from this analysis reinforce the important role of DIFICID in the treatment of CDAD, especially its use as a front-line agent," said Sherwood Gorbach, Chief Scientific Officer and Senior Vice President of Optimer. "We are encouraged by these results and look forward to conducting future clinical trials to explore the potential benefits of DIFICID in patients with cancer and others who are at high risk for CDAD."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Drug major Johnson & Johnson Tuesday said it expects higher earnings and sales for its fiscal 2017, which are below market estimates. The company also reported solid fourth-quarter results, with adjusted earnings above market estimates, while sales missed their view, despite a growth. In pre-market activity on the NYSE, Johnson & Johnson shares were losing 1.68 percent. Verizon Communications Inc. (VZ) reported fourth-quarter adjusted earnings per share of $0.86 compared to $0.89, prior year. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $0.89 for the quarter. Analysts' estimates typically exclude special items.... German business software maker SAP AG on Tuesday raised its forecast for fiscal 2017 and 2020, after reporting higher profit and revenues in its fourth quarter. For fiscal 2017, SAP now expects non-IFRS operating profit in a range of 6.8 billion euros to 7.0 billion euros at constant currencies, compared to 6.63 billion euros in 2016.
comments powered by Disqus
Follow RTT